Itoh K, Balch C M, Murray J L, Parkinson D R, Markowitz A B, Talpaz M, Lee K, Zukiwski A A, Ross M I, Legha S S
Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston.
In Vivo. 1991 Nov-Dec;5(6):647-53.
Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies resulted in both transient nonresponsiveness of TILs to IL-2 and transient decrease in the number of live tumour cells in most melanoma patients.
研究了基于白细胞介素-2的生物疗法之前和/或之后黑色素瘤肿瘤浸润淋巴细胞（TILs）的免疫特性。治疗前采集的TILs，包括用于过继性转移的TILs，在白细胞介素-2培养中增殖良好，并表现出相对局限于自体肿瘤细胞的细胞毒性。相比之下，基于白细胞介素-2的治疗期间或结束时的TILs在白细胞介素-2培养中不增殖。即使在白细胞介素-2治疗结束后45天采集的肿瘤TILs，在白细胞介素-2培养中也仅有适度增殖，并表现出主要组织相容性复合体（MHC）非限制性细胞毒性。在所有9例转移性黑色素瘤患者中，无论其临床反应如何（2例部分缓解、2例微小缓解、2例疾病稳定和3例疾病进展），基于白细胞介素-2的治疗期间或结束时黑色素瘤产生的活肿瘤细胞数量均显著减少。总体而言，这些结果表明，目前基于白细胞介素-2的疗法导致大多数黑色素瘤患者的TILs对白细胞介素-2产生短暂无反应性，并使活肿瘤细胞数量短暂减少。
